MYCOSIS FUNGOIDES
Clinical trials for MYCOSIS FUNGOIDES explained in plain language.
Never miss a new study
Get alerted when new MYCOSIS FUNGOIDES trials appear
Sign up with your email to follow new studies for MYCOSIS FUNGOIDES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat skin cancer
Disease control TerminatedThis early-phase trial tests two drugs, mogamulizumab and brentuximab vedotin, given together to people with a rare type of skin lymphoma (CTCL or mycosis fungoides) that has not responded to prior treatment. The main goal is to see if the combination is safe and to find the best…
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take aim at tough lymphomas in first human test
Disease control OngoingThis early-phase trial tests a new type of immunotherapy for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are genetically modified to recognize and attack can…
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo targets rare skin cancer in small trial
Disease control OngoingThis study tests whether combining pembrolizumab (an immunotherapy) with gemcitabine (a chemotherapy drug) can shrink tumors in people with advanced mycosis fungoides or Sézary syndrome, rare types of skin lymphoma. The trial enrolled 14 adults who had already tried at least one …
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Supercharged immune cells aim to stop lymphoma comeback
Disease control OngoingThis early-phase trial tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma who have had a stem cell transplant. The treatment uses the patient's own T cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD30. The m…
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New pill shows promise for rare skin cancer in early trial
Disease control OngoingThis early-phase trial tests a new drug called tulmimetostat (DZR123) in 24 people with advanced mycosis fungoides or Sézary syndrome, rare types of skin lymphoma. Participants must have tried at least one prior treatment. The study aims to see if the drug is safe and tolerable, …
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Promising skin cancer trial pulled before it even started
Disease control TerminatedThis study was designed to test a new drug called Resimmune against an oral medication (Zolinza) for people with a type of skin lymphoma called mycosis fungoides. The goal was to see if a single four-day treatment could completely clear skin lesions. However, the trial was withdr…
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE2 • Sponsor: Virogen Biotechnology Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy targets early skin cancer: hope or hype?
Disease control TerminatedThis pilot study tests whether combining a targeted drug (mogamulizumab) with ultraviolet light therapy (phototherapy) can better control early-stage mycosis fungoides, a type of skin lymphoma. Twenty adults with stage IA-IIA disease will receive the drug for 8 cycles and add pho…
Matched conditions: MYCOSIS FUNGOIDES
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug shows promise for controlling rare skin cancers
Disease control OngoingThis study tests a drug called brentuximab vedotin in 79 people with rare skin lymphomas (ALCL, mycosis fungoides, or lymphomatoid papulosis) that have a marker called CD30. The goal is to see if the drug can shrink or control the cancer. Participants receive the drug every 3 wee…
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for rare skin cancer: targeted antibody tested in china
Disease control OngoingThis study tests a drug called mogamulizumab in 23 Chinese adults with mycosis fungoides or Sézary syndrome, two types of skin lymphoma that have not responded to previous treatments. The drug is given as an IV infusion and aims to shrink or eliminate cancer in the skin, lymph no…
Matched conditions: MYCOSIS FUNGOIDES
Phase: PHASE4 • Sponsor: Kyowa Kirin China Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 18:41 UTC
-
Can a body wash improve skin bacteria in lymphoma patients?
Knowledge-focused ENROLLING_BY_INVITATIONThis pilot study looks at how daily use of CLn Body Wash (a mild bleach solution) affects the bacteria on skin lesions in people with mycosis fungoides, a type of cutaneous T cell lymphoma. The main goal is to see if the wash reduces harmful Staphylococcus aureus bacteria. The st…
Matched conditions: MYCOSIS FUNGOIDES
Sponsor: Northwestern University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC